Published in Cell Cycle on January 01, 2014
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Cancer-related inflammation. Nature (2008) 34.21
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Chemokines: a new classification system and their role in immunity. Immunity (2000) 13.03
The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol (2006) 12.80
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 9.25
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86
A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med (2006) 6.86
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med (1993) 5.32
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 5.28
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 5.12
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med (1999) 4.15
Symptoms in gastro-oesophageal reflux disease. Lancet (1990) 4.10
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85
Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature (2000) 3.81
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
Chemokines: multiple levels of leukocyte migration control. Trends Immunol (2004) 3.32
Barrett's esophagus. Gastroenterology (2002) 3.27
The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol (2000) 3.26
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest (2008) 3.17
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
Cancer: Inflaming metastasis. Nature (2009) 3.09
Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis (2004) 3.02
The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest (1995) 3.00
The chemokine receptor D6 limits the inflammatory response in vivo. Nat Immunol (2005) 2.98
Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat Rev Immunol (2006) 2.92
The chemokine superfamily revisited. Immunity (2012) 2.83
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem (2002) 2.67
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
2. Cytokines and chemokines. J Allergy Clin Immunol (2003) 2.54
American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology (2011) 2.50
Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell (2007) 2.48
The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol (2006) 2.42
Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol (1999) 2.38
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut (2007) 2.28
How chemokines invite leukocytes to dance. Nat Immunol (2008) 2.18
Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18
Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer (2003) 2.03
The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J Biol Chem (2000) 1.86
Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med (2000) 1.83
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell (2009) 1.82
Cxc chemokine receptor expression on human endothelial cells. Cytokine (1999) 1.79
Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer (2008) 1.78
Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer (2003) 1.75
Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol (2001) 1.72
Stepping out of the flow: capillary extravasation in cancer metastasis. Clin Exp Metastasis (2007) 1.68
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev (2007) 1.49
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet (2011) 1.47
CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem (2010) 1.47
The biological relevance of chemokine-proteoglycan interactions. Biochem Soc Trans (2006) 1.44
Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer (2009) 1.41
Incidence of cancer of the esophagus in the US by histologic type. Cancer (1988) 1.40
Chemokines as mediators of angiogenesis. Thromb Haemost (2007) 1.40
Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut (2002) 1.38
Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer (2002) 1.37
Tumor angiogenesis: cause or consequence of cancer? Cancer Res (2007) 1.35
Endogenous DNA damage and mutation. Trends Genet (2001) 1.34
Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res (2009) 1.34
The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J (2006) 1.33
The molecular biology of esophageal adenocarcinoma. J Surg Oncol (2005) 1.32
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res (2008) 1.30
Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res (2010) 1.26
Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene (2006) 1.22
Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control (2007) 1.20
The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta (2011) 1.18
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.17
Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. Carcinogenesis (2009) 1.17
The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci (2011) 1.15
Dietary patterns and risk of squamous-cell carcinoma and adenocarcinoma of the esophagus and adenocarcinoma of the gastric cardia: a population-based case-control study in Sweden. Nutr Cancer (2006) 1.15
HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One (2012) 1.15
Oxidative and nitrative DNA damage as biomarker for carcinogenesis with special reference to inflammation. Antioxid Redox Signal (2006) 1.14
Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res (2010) 1.11
Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res (1997) 1.11
Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ (2009) 1.07
Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget (2014) 1.02
A family tree of vertebrate chemokine receptors for a unified nomenclature. Dev Comp Immunol (2011) 0.99
Inflammatory and microRNA gene expression as prognostic classifier of Barrett's-associated esophageal adenocarcinoma. Clin Cancer Res (2010) 0.99
Barrett's esophagus. J Gastroenterol Hepatol (2011) 0.97
Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett (2008) 0.96
Esophageal malignancy: a growing concern. World J Gastroenterol (2012) 0.92
H. pylori infection is a key risk factor for proximal gastric cancer. Dig Dis Sci (2010) 0.89
Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol (2012) 0.89
Under pressure: stromal fibroblasts change their ways. Cell (2005) 0.89
Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res (2010) 0.89
Telomere length and telomerase subunits as diagnostic and prognostic biomarkers in Barrett carcinoma. Cancer (2008) 0.88
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
EMT and dissemination precede pancreatic tumor formation. Cell (2012) 9.27
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature (2003) 8.14
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature (2004) 6.82
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol (2011) 6.16
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res (2007) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A (2010) 4.97
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol (2004) 4.74
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proc Natl Acad Sci U S A (2008) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst (2010) 3.08
The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev (2010) 3.02
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology (2007) 2.93
Human embryonic stem cells have a unique epigenetic signature. Genome Res (2006) 2.89
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology (2008) 2.71
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther (2009) 2.61
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev (2010) 2.37
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology (2009) 2.23
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther (2010) 2.21
An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther (2008) 2.21
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Cytosine methylation dysregulation in neonates following intrauterine growth restriction. PLoS One (2010) 2.10
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther (2009) 2.01
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res (2011) 1.98
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood (2012) 1.98
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood (2008) 1.95
Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis. Inflamm Bowel Dis (2007) 1.94
Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res (2004) 1.93
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A (2012) 1.90
Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res (2003) 1.90
Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am J Surg Pathol (2007) 1.90
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res (2006) 1.89
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther (2005) 1.83
Establishment and characterization of a bona fide Barrett esophagus-associated adenocarcinoma cell line. Cancer Biol Ther (2008) 1.83
Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res (2006) 1.82
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic Acids Res (2009) 1.80
Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS One (2011) 1.79
The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther (2009) 1.78
A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther (2011) 1.76
Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther (2011) 1.76
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2004) 1.76
Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology (2009) 1.76
Precursors to pancreatic cancer. Gastroenterol Clin North Am (2007) 1.75
Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg (2007) 1.74
Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther (2004) 1.74
Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem (2002) 1.72
Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol (2012) 1.71
Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res (2008) 1.69
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci U S A (2007) 1.68
Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res (2009) 1.66
Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin Cancer Res (2009) 1.65
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann Surg Oncol (2003) 1.60
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res (2011) 1.59
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res (2003) 1.58
Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology (2007) 1.58
Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A (2011) 1.56
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res (2010) 1.54
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood (2010) 1.53
Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol (2013) 1.52
Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (2013) 1.49
Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein. Mol Cancer Ther (2007) 1.49
Outcome from therapeutic hypothermia and EEG. J Clin Neurophysiol (2011) 1.48
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood (2006) 1.48
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet (2011) 1.47